{"id":"pegaptanib","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Vascular endothelial growth factor A","category":"target"},{"label":"VEGFA","category":"gene"},{"label":"S01LA03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Exudative age-related macular degeneration","category":"indication"},{"label":"Bausch And Lomb Inc","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Bausch Health","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pegaptanib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:04.278523+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:30:11.084974+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pegaptanib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:30:11.923876+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vascular endothelial growth factor A antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:12.497783+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201421/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:12.396926+00:00"}},"allNames":"macugen","offLabel":[],"synonyms":["pegaptanib","pegaptanib sodium","macugen","pegaptanib octasodium","EYE001","NX1838"],"timeline":[{"date":"2004-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from VALEANT PHARMS LLC to Bausch And Lomb Inc"},{"date":"2004-12-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Valeant Pharms Llc)"}],"aiSummary":"Macugen (pegaptanib) is a small molecule drug that targets vascular endothelial growth factor A (VEGF-A), a protein involved in the growth of new blood vessels. It was originally developed by Valeant Pharms LLC and is now owned by Bausch and Lomb Inc. Macugen was FDA-approved in 2004 for the treatment of exudative age-related macular degeneration. The drug is off-patent, meaning it is no longer protected by patents, and there are currently no generic manufacturers. Macugen is used to slow the progression of vision loss in patients with this condition.","approvals":[{"date":"2004-12-17","orphan":false,"company":"VALEANT PHARMS LLC","regulator":"FDA"}],"brandName":"Macugen","ecosystem":[{"indication":"Exudative age-related macular degeneration","otherDrugs":[{"name":"aflibercept","slug":"aflibercept","company":"Regeneron Pharmaceuticals"},{"name":"brolucizumab","slug":"brolucizumab","company":"Novartis Pharms Corp"},{"name":"faricimab","slug":"faricimab","company":"Genentech Inc"},{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":900000000}],"mechanism":{"target":"Vascular endothelial growth factor A","novelty":"Follow-on","targets":[{"gene":"VEGFA","source":"DrugCentral","target":"Vascular endothelial growth factor A","protein":"Vascular endothelial growth factor A"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Macugen is a 28-mer aptamer that specifically binds to the 165 amino acid isoform of VEGF-A, preventing its interaction with its receptor and subsequent signaling pathways that promote angiogenesis."},"commercial":{"launchDate":"2004","_launchSource":"DrugCentral (FDA 2004-12-17, VALEANT PHARMS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4905","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=pegaptanib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pegaptanib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:16:01.906561","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:14.267547+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"verteporfin","drugSlug":"verteporfin","fdaApproval":"2000-04-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ranibizumab","drugSlug":"ranibizumab","fdaApproval":"2006-06-30","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"brolucizumab","drugSlug":"brolucizumab","fdaApproval":"2019-10-07","relationship":"same-class"},{"drugName":"bevacizumab","drugSlug":"bevacizumab","fdaApproval":"2004-02-26","relationship":"same-class"},{"drugName":"faricimab","drugSlug":"faricimab","fdaApproval":"2022-01-28","relationship":"same-class"}],"genericName":"pegaptanib","indications":{"approved":[{"name":"Exudative age-related macular degeneration","source":"DrugCentral","snomedId":414173003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":900000000,"prevalenceMethod":"curated","prevalenceSource":"Retina, 2018 (PMID:29059101)"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bausch And Lomb Inc","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"verteporfin","brandName":"verteporfin","genericName":"verteporfin","approvalYear":"2000","relationship":"same-class"},{"drugId":"ranibizumab","brandName":"ranibizumab","genericName":"ranibizumab","approvalYear":"2006","relationship":"same-class"},{"drugId":"aflibercept","brandName":"aflibercept","genericName":"aflibercept","approvalYear":"2011","relationship":"same-class"},{"drugId":"brolucizumab","brandName":"brolucizumab","genericName":"brolucizumab","approvalYear":"2019","relationship":"same-class"},{"drugId":"bevacizumab","brandName":"bevacizumab","genericName":"bevacizumab","approvalYear":"2004","relationship":"same-class"},{"drugId":"faricimab","brandName":"faricimab","genericName":"faricimab","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00790803","phase":"NA","title":"Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":["Uveitis","Cystoid Macular Edema"],"enrollment":5,"completionDate":"2012-03"},{"nctId":"NCT01573572","phase":"PHASE4","title":"Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-04-22","conditions":["Age-Related Macular Degeneration","Retinal Vein Occlusion","Diabetic Macular Edema"],"enrollment":131,"completionDate":"2019-11-14"},{"nctId":"NCT00787319","phase":"","title":"Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":["Age-related Macular Degeneration"],"enrollment":108,"completionDate":"2012-06"},{"nctId":"NCT00549055","phase":"","title":"A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":38,"completionDate":"2009-10"},{"nctId":"NCT00605280","phase":"PHASE2,PHASE3","title":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":["Macular Edema Associated With Diabetes Mellitus"],"enrollment":317,"completionDate":"2011-07"},{"nctId":"NCT01712035","phase":"","title":"Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-10","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":44,"completionDate":"2017-12-05"},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":["Macular Disease"],"enrollment":1000,"completionDate":"2024-12"},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":["Macular Disease"],"enrollment":1000,"completionDate":"2024-03"},{"nctId":"NCT00242580","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":["Macular Degeneration","Choroidal Neovascularization"],"enrollment":111,"completionDate":""},{"nctId":"NCT00845273","phase":"","title":"Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":["Macular Degeneration"],"enrollment":3538,"completionDate":"2014-02"},{"nctId":"NCT01218230","phase":"NA","title":"Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia","status":"WITHDRAWN","sponsor":"L.V. Prasad Eye Institute","startDate":"2010-12","conditions":["Myopic Choroidal Neovascular Membrane"],"enrollment":0,"completionDate":"2012-07"},{"nctId":"NCT01281098","phase":"PHASE2","title":"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2010-03","conditions":["High Risk Proliferative Diabetic Retinopathy","Diabetes Mellitus Type I","Diabetes Mellitus Type II"],"enrollment":22,"completionDate":"2013-02"},{"nctId":"NCT00320775","phase":"PHASE1","title":"Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2005-06","conditions":["Macular Degeneration"],"enrollment":51,"completionDate":"2008-08"},{"nctId":"NCT00820742","phase":"","title":"Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2008-02","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":0,"completionDate":"2009-05"},{"nctId":"NCT01175070","phase":"PHASE4","title":"Intravitreal Macugen for Ischaemic Diabetic Macular Oedema","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-01","conditions":["Diabetic Macular Oedema"],"enrollment":30,"completionDate":"2013-03"},{"nctId":"NCT00709657","phase":"NA","title":"The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":["Macular Degeneration","Regional Blood Flow","Vascular Endothelial Growth Factor"],"enrollment":8,"completionDate":"2011-11"},{"nctId":"NCT00406107","phase":"PHASE4","title":"Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2006-01","conditions":["Branch Retinal Vein Occlusion"],"enrollment":20,"completionDate":"2008-04"},{"nctId":"NCT01589718","phase":"PHASE3","title":"A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy","status":"WITHDRAWN","sponsor":"Greater Houston Retina Research","startDate":"2012-04","conditions":["Proliferative Diabetic Retinopathy"],"enrollment":0,"completionDate":"2014-03"},{"nctId":"NCT01189461","phase":"PHASE3","title":"Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01","conditions":["Anti- VGF Inhibitor","Diabetic Macular Edema","Diabetic Retinopathy"],"enrollment":46,"completionDate":"2012-07"},{"nctId":"NCT01100307","phase":"PHASE3","title":"A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05","conditions":["Macular Edema","Diabetic Mellitus","Retinal Disease"],"enrollment":243,"completionDate":"2012-08"},{"nctId":"NCT01486238","phase":"PHASE4","title":"Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study","status":"COMPLETED","sponsor":"Valley Retina Institute","startDate":"2009-04","conditions":["Diabetic Macular Edema"],"enrollment":72,"completionDate":"2011-10"},{"nctId":"NCT00460408","phase":"","title":"Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":["Macular Degeneration"],"enrollment":501,"completionDate":"2012-02"},{"nctId":"NCT00804934","phase":"","title":"Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis","status":"COMPLETED","sponsor":"Retina Institute of Hawaii","startDate":"2008-02","conditions":["Wet AMD"],"enrollment":100,"completionDate":"2009-01"},{"nctId":"NCT00446381","phase":"NA","title":"Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-10","conditions":["Proliferative Diabetic Retinopathy","Diabetic Macular Edema"],"enrollment":28,"completionDate":"2008-09"},{"nctId":"NCT00858208","phase":"","title":"Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":86,"completionDate":"2011-04"},{"nctId":"NCT00327470","phase":"PHASE4","title":"An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-07","conditions":["Age Related Macular Degeneration (AMD)","Macular Degeneration","Choroidal Neovascularization (CNV)"],"enrollment":288,"completionDate":"2009-08"},{"nctId":"NCT01487044","phase":"","title":"A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema","status":"AVAILABLE","sponsor":"Retina Institute of Hawaii","startDate":"","conditions":["Diabetic Macular Edema"],"enrollment":0,"completionDate":""},{"nctId":"NCT01487070","phase":"PHASE1","title":"A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Retina Institute of Hawaii","startDate":"2011-04","conditions":["PDR"],"enrollment":5,"completionDate":"2011-07"},{"nctId":"NCT01486771","phase":"PHASE4","title":"Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)","status":"UNKNOWN","sponsor":"Valley Retina Institute","startDate":"2007-11","conditions":["Proliferative Diabetic Retinopathy"],"enrollment":30,"completionDate":"2014-02"},{"nctId":"NCT00788177","phase":"PHASE3","title":"Subretinal Macugen® for Neovascular Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"Klinikum Ludwigshafen","startDate":"2008-11","conditions":["Age-related Macular Degeneration"],"enrollment":10,"completionDate":"2012-12"},{"nctId":"NCT00735943","phase":"","title":"Macugen Observational Study","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-11","conditions":["Vascular Endothelial Growth Factor","Macular Degeneration"],"enrollment":22,"completionDate":"2010-08"},{"nctId":"NCT00239928","phase":"PHASE2","title":"Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":["Macular Degeneration"],"enrollment":61,"completionDate":"2008-11"},{"nctId":"NCT01245387","phase":"","title":"Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":["Macular Degeneration","Age-related Macular Degeneration","Neovascular Macular Degeneration"],"enrollment":1001,"completionDate":"2009-12"},{"nctId":"NCT00324116","phase":"PHASE4","title":"Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":["Macular Degeneration"],"enrollment":81,"completionDate":"2008-08"},{"nctId":"NCT00531336","phase":"PHASE2","title":"MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen","status":"COMPLETED","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2006-07","conditions":["Macular Degeneration"],"enrollment":60,"completionDate":"2008-12"},{"nctId":"NCT00295828","phase":"PHASE1","title":"A Pilot Study for the Treatment of Iris Neovascularization With Macugen","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2006-01","conditions":["Iris Neovascularization","Diabetic Retinopathy"],"enrollment":10,"completionDate":"2008-09"},{"nctId":"NCT00358423","phase":"PHASE1,PHASE2","title":"The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-07","conditions":["Cystoid Macular Edema"],"enrollment":1,"completionDate":"2007-02"},{"nctId":"NCT00346983","phase":"PHASE1,PHASE2","title":"Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-06","conditions":["Cystoid Macular Edema"],"enrollment":4,"completionDate":"2007-05"},{"nctId":"NCT00150202","phase":"PHASE3","title":"Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":["Macular Degeneration"],"enrollment":90,"completionDate":"2006-10"},{"nctId":"NCT00088283","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-05","conditions":["Retinal Vein Occlusion"],"enrollment":90,"completionDate":""},{"nctId":"NCT00354445","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD","status":"UNKNOWN","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-06","conditions":["Age-Related Macular Degeneration (AMD)"],"enrollment":1000,"completionDate":""},{"nctId":"NCT00312351","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-04","conditions":["Macular Degeneration"],"enrollment":262,"completionDate":"2006-11"},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":["Age-Related Macular Degeneration"],"enrollment":360,"completionDate":"2008-10"},{"nctId":"NCT00272766","phase":"NA","title":"Macugen for Histoplasmosis","status":"TERMINATED","sponsor":"Barnes Retina Institute","startDate":"2006-02","conditions":["Ocular Histoplasmosis","Choroidal Neovascularization"],"enrollment":24,"completionDate":"2007-05"},{"nctId":"NCT00321997","phase":"PHASE2,PHASE3","title":"A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2001-05","conditions":["Age-Related Macular Degeneration"],"enrollment":540,"completionDate":"2007-10"},{"nctId":"NCT00215670","phase":"PHASE2,PHASE3","title":"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-11","conditions":["Age-Related Macular Degeneration"],"enrollment":125,"completionDate":"2006-05"},{"nctId":"NCT00087763","phase":"PHASE2","title":"Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-03","conditions":["Macular Degeneration"],"enrollment":135,"completionDate":"2006-05"},{"nctId":"NCT00040313","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-10","conditions":["Diabetic Macular Edema"],"enrollment":0,"completionDate":"2005-02"},{"nctId":"NCT00088192","phase":"NA","title":"Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-07","conditions":["Macular Degeneration"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000171612","MMSL":"19106","NDDF":"008794","UNII":"2H1PA8H1EN","VUID":"4024940","VANDF":"4024940","INN_ID":"8215","RXNORM":"498509","UMLSCUI":"C1531015","chemblId":"CHEMBL1201421","ChEMBL_ID":"CHEMBL2108752","KEGG_DRUG":"D05386","DRUGBANK_ID":"DB04895","PUBCHEM_CID":"56603655","SNOMEDCT_US":"416058004","IUPHAR_LIGAND_ID":"6836","MESH_SUPPLEMENTAL_RECORD_UI":"C495058"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2004-","companyName":"Valeant Pharms Llc","relationship":"Original Developer"},{"period":"present","companyName":"Bausch And Lomb Inc","relationship":"Current Owner"}],"publicationCount":511,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01LA03","allCodes":["S01LA03"]},"biosimilarFilings":[],"originalDeveloper":"Valeant Pharms Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Bausch And Lomb Inc","companyId":"bausch","modality":"Small Molecule","firstApprovalDate":"2004","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-12-17T00:00:00.000Z","mah":"VALEANT PHARMS LLC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Macugen","application_number":"EMEA/H/C/000620"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Macugen","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:14.267547+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}